IgGenix: Funding, Investors & Team (Oct 2026)
IgGenix is a biotechnology company, directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. IgGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade.
IgGenix has raised $75.0M across 4 funding rounds on record, the most recent a Series B of $40.0M announced in Feb 2023.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
IgGenix Company Profile and Key Stats
Latest funding round on record: Feb 2023.
IgGenix Funding Rounds
1 of 4 rounds was announced without a disclosed amount and is excluded from the total.
IgGenix raised $10.0M in an undisclosed round announced in Aug 2020.
11 months later, a Series A of $25.0M was announced in Jul 2021.
9 months later, a Series A was announced in Apr 2022 with no disclosed amount.
10 months later, a Series B of $40.0M was announced in Feb 2023.
IgGenix Founders and Leadership Team
Contact details for the IgGenix team: 2 of 3 have an email address on file.
Start 14-day free trial →IgGenix Funding Compared to Other Biotechnology Startups
IgGenix's latest round of $40.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like IgGenix in Biotechnology and San Francisco
Companies Similar to IgGenix
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
IgGenix Funding FAQs
What does IgGenix do?
IgGenix is a biotechnology company, directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. IgGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade.
How much funding has IgGenix raised?
IgGenix has raised $75.0M across 4 rounds on record. The most recent is a Series B of $40.0M announced in Feb 2023.
When did IgGenix last raise funding?
IgGenix's most recent funding round on record is a Series B of $40.0M, announced in Feb 2023.
Who founded IgGenix?
FundedIQ lists Bruce Hironaka (Founder), Stephen Quake (Founder) at IgGenix.
Who is the CEO of IgGenix?
Jessica Grossman MD is listed as CEO at IgGenix.
Where is IgGenix headquartered?
IgGenix is based in San Francisco, California, United States.
How many employees does IgGenix have?
IgGenix is in the 1-10 employee band.
How does IgGenix's funding compare to other Biotechnology startups?
IgGenix's latest round of $40.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's IgGenix Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for IgGenix is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.